Skip to main content

Table 3 Study endpoints after 3 years of follow-up, n = 281

From: Serum neutrophil gelatinase-associated lipocalin has an advantage over serum cystatin C and glomerular filtration rate in prediction of adverse cardiovascular outcome in patients with ST-segment elevation myocardial infarction

Study endpoint

Value

Cardiovascular death, n (%)

43 (15.3)

Recurrent myocardial infarction, n (%)

40 (14.2)

Stroke, n (%)

12 (4.3)

Hospital admission due to unstable angina, n (%)

81 (28.8)

Acute decompensated heart failure, n (%)

23 (8.2)

Combined endpoint, n (%)

199 (70.8)